By Market Intelligence Team

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Eli Lilly and Co. could face generic competition on its antidepressant drug Prozac as early as August 3, 2001 following a federal appeals court ruling in July 2001, that it would not reconsider an earlier ruling that found the drug company's 2003 patent invalid. Lilly had hoped to extend its patent on the drug through 2003, and now plans to appeal the decision to the U.S. Supreme Court. "We still feel it's very valid . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

By Market Intelligence Team

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Eli Lilly and Co. could face generic competition on its antidepressant drug Prozac as early as August 3, 2001 following a federal appeals court ruling in July 2001, that it would not reconsider an earlier ruling that found the drug company's 2003 patent invalid. Lilly had hoped to extend its patent on the drug through 2003, and now plans to appeal the decision to the U.S. Supreme Court. "We still feel it's very valid . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options
OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Eli Lilly and Co. could face generic competition on its antidepressant drug Prozac as early as August 3, 2001 following a federal appeals court ruling in July 2001, that it would not reconsider an earlier ruling that found the drug company's 2003 patent invalid. Lilly had hoped to extend its patent on the drug through 2003, and now plans to appeal the decision to the U.S. Supreme Court. "We still feel it's very valid . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!